Hematology (all articles)
Isatuximab plus pomalidomide and low-dose dexamethasone vs. pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
21 Feb, 2022 | 08:13h | UTCIsatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
16 Feb, 2022 | 10:13h | UTC
Commentary on Twitter
A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig
— Eric Topol (@EricTopol) February 15, 2022
Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study.
16 Feb, 2022 | 08:39h | UTC
A large cohort of patients with nephrotic syndrome showed the risk of arterial thromboembolism (HR = 3.11), venous thromboembolism (HR = 7.11), and bleeding (HR = 4.02) was greatly increased after adjusting for confounders.
15 Feb, 2022 | 08:47h | UTCRisk of arterial thromboembolism, venous thromboembolism, and bleeding in patients with nephrotic syndrome: A population-based cohort study – American Journal of Medicine (link to abstract – $ for full-text)
Review: Management of venous thromboembolism in pregnancy.
13 Feb, 2022 | 21:57h | UTCManagement of venous thromboembolism in pregnancy – Thrombosis Research
Related:
Management of high-risk pulmonary embolism in pregnancy.
Study: Diagnosis of Pulmonary Embolism During Pregnancy
Imaging is the only way to diagnose blood clots in pregnancy
Betibeglogene Autotemcel gene therapy for Non–beta0/beta0 Genotype beta-thalassemia.
13 Feb, 2022 | 21:46h | UTCBetibeglogene Autotemcel Gene Therapy for Non–β0/β0 Genotype β-Thalassemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Visual Abstract: Betibeglogene Autotemcel Gene Therapy for Non–β0/β0 Genotype β-Thalassemia. https://t.co/2GOCGxrruv pic.twitter.com/zLvuuuByXN
— NEJM (@NEJM) February 8, 2022
IDSA Updated Covid-19 Guideline now supports the use of convalescent plasma in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease.
9 Feb, 2022 | 10:15h | UTC
Commentary on Twitter
Update Alert: Revised recommendation on the use of #convalescentplasma in ambulatory patients w/ COVID-19 at high risk of progression to severe disease w/ no other treatment options.
📄: https://t.co/YRCxtdilXT#COVID19Guidelines @JGPharmD @adarsh_bhimraj @RMKGandhi @ShohamTxID pic.twitter.com/KpXnywH362
— IDSA (@IDSAInfo) February 8, 2022
Australasian Consensus Guidelines for the use of antifungal agents in the hematology-oncology setting.
9 Feb, 2022 | 08:49h | UTCConsensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
Expert Consensus: Treatment algorithm in cancer-associated thrombosis.
9 Feb, 2022 | 08:42h | UTC
Review | Prehospital plasma transfusion: what does the literature show?
9 Feb, 2022 | 08:22h | UTC
Review | Emergency blood transfusion for trauma and perioperative resuscitation.
9 Feb, 2022 | 08:22h | UTC
In patients taking anticoagulants (DOAC or Warfarin), a respiratory tract infection not treated with antibiotics is associated with a greater than twofold increase in the risk of bleeding during the next 0-14 days.
8 Feb, 2022 | 08:46h | UTC
Commentary on Twitter
In new research of 1208 oral anticoagulant users, a greater than twofold increase was seen in the risk of major bleeding & clinically relevant non-major bleeding in the 0-14 days after a respiratory tract infection for which no antibiotics were prescribed https://t.co/wMIb2eDBKk
— The BMJ (@bmj_latest) December 21, 2021
DIC in Pregnancy: Pathophysiology, clinical characteristics, diagnostic scores, and treatments.
2 Feb, 2022 | 08:27h | UTC
Review: Diagnosis and Management of Multiple Myeloma.
2 Feb, 2022 | 08:11h | UTCDiagnosis and Management of Multiple Myeloma: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis and Management of Multiple Myeloma – JAMA
Registry study in Denmark found an increased bleeding risk with the association of systemic Fluconazole and Apixaban (OR 3.5; 95% CI, 1.4-10.6).
1 Feb, 2022 | 08:13h | UTC
RCT: Olanzapine may improve the control of vomiting in the delayed phase in children receiving highly emetogenic chemotherapy.
30 Jan, 2022 | 14:13h | UTCEfficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial – Journal of Pediatric Hematology/Oncology (link to abstract – $ for full-text)
Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
30 Jan, 2022 | 14:11h | UTCOriginal Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
Related:
Clinical practice guideline on immune checkpoint inhibitor-related adverse events.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)
Systematic Review: Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism.
30 Jan, 2022 | 14:04h | UTC
RCT: Axicabtagene Ciloleucel as second-line therapy for Large B-Cell Lymphoma.
30 Jan, 2022 | 13:41h | UTC
Commentary on Twitter
In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy. #ASH21 https://t.co/V1WfVJ2k9V pic.twitter.com/ZHUhx8es27
— NEJM (@NEJM) December 11, 2021
ELSO Guidelines for anticoagulation in adult and pediatric patients using extracorporeal membrane oxygenation (ECMO).
28 Jan, 2022 | 08:26h | UTC2021 ELSO Adult and Pediatric Anticoagulation Guidelines – ASAIO Journal
Commentary on Twitter
The updated @ELSOOrg adult & pediatric anticoagulation guidelines just out, open access, on @asaiojournal
🩸anticoagulants
🩸therapeutic monitoring of anticoagulants
🩸management of bleeding & thrombotic complications#FOAMcc #FOAMecmo #PedsICU
🖇 https://t.co/sC8iQK6YL0 pic.twitter.com/hkbVoNBDkR— ELSO (@ELSOOrg) January 21, 2022
RCT: In patients with chronic myeloid leukemia in chronic phase resistant/intolerant to ≥2 tyrosine kinase inhibitors, Asciminib resulted in better disease response compared to Bosutinib.
28 Jan, 2022 | 08:00h | UTCNews Release: Asciminib Superior to Bosutinib in Chronic-Phase CML – ASH Clinical News
Iron deficiency anemia: pathophysiology, assessment, practical management.
27 Jan, 2022 | 09:30h | UTC
ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question in children.
25 Jan, 2022 | 09:33h | UTCSee complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
24 Jan, 2022 | 08:28h | UTCA blood atlas of COVID-19 defines hallmarks of disease severity and specificity – Cell
Commentary on Twitter:
A simple😉one-page summary of everything you need to know about Covid hallmarks of severity in the blood, how it differs from flu, sepsis, and much morehttps://t.co/s81Qb2SXmu @CellCellPress @KnightGenetics
(actually quite a rich resource @UniofOxford) pic.twitter.com/bk0AxwLItn— Eric Topol (@EricTopol) January 22, 2022
Review: Histiocytic disorders.
24 Jan, 2022 | 08:02h | UTCHistiocytic disorders – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Histiocytic disorders (if the link is paywalled, try this one)
Commentary on Twitter
Haemophagocytic lympho #histiocytosis is a syndrome of extreme #immune activation; common manifestations include involvement of the central nervous system, hepatitis or acute liver failure.https://t.co/heXWqru8wW pic.twitter.com/1A0SFIhkwR
— Nature Reviews Disease Primers (@DiseasePrimers) January 21, 2022